FIELD: medicine.
SUBSTANCE: invention can be used for treating recurrent acute myeloid leukaemia (AML) following the transplantation of allogenic haemopoietic stem cells. That is ensured by chemotherapy followed by administering (taking into account donor's leukocyte chimerism) donor's bone marrow lymphocytes in a combination with interleukin 2 (IL-2). The chemotherapy is conducted by the intravenous administration of anti-tumour preparations of cytabarine 100 mg/m2 twice a day for 7 days and indarubicine 12 mg/m2 1 time a day within 3 days. With underlying myelotoxic agranulocytosis with a granulocyte count of less than 0.5×109/l, the donor's bone marrow lymphocytes are transfused is a dose of 1×107 CD3+cells/kg of the patient's body weight that is followed by the intravenous drop-by-drop administration of IL-2 in a dose of 6 mln International Units 1-2 hours later. The 100% absence of the donor's leukocyte chimerism and any signs of the graft vs. host disease, the following two donor's lymphocyte transfusions and IL-2 infusions in a dose of 6 mln International Units are performed the first of the two donor's bone marrow lymphocyte transfusions is performed in a dose of 5×107 CD3+cells/kg, and the second one - in a dose of 1×108 CD3+cells/kg. The transfusion cycle makes 2-4 weeks. That is followed by therapeutic supporting course of IL-2 administration in a dose of 2 mln International Units a day for 5 days intravenously; the course cycle makes 4-5 weeks with the supporting therapy lasting for 2 years.
EFFECT: higher clinical effectiveness of post-transplantation recurrence, achieved long-lasting recurrent remissions, higher overall survival rate in the patients with acute myeloid leukaemia.
2 ex
